These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 205361)

  • 21. Clinical immunotherapy trials of bacterial components derived from Mycobacteria and Nocardia.
    Vosika GJ
    J Biol Response Mod; 1983; 2(4):321-42. PubMed ID: 6358421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor regression after intralesional injection of mycobacterial components emulsified in 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (squalene), 2,6,10,15,19,23-hexamethyltetracosane (squalane), peanut oil, or mineral oil.
    Yarkoni E; Rapp HJ
    Cancer Res; 1979 May; 39(5):1518-20. PubMed ID: 427795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria.
    Yarkoni E; Rapp HJ
    Cancer Res; 1979 Feb; 39(2 Pt 1):535-7. PubMed ID: 761228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of a guinea pig hepatoma with living BCG: a frozen liquid and a lyophilized preparation are equally active.
    Zbar B; Ribi E; Rapp HJ
    Cancer; 1977 Dec; 40(6):2930-2. PubMed ID: 201359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor regression caused by endotoxins and mycobacterial fractions.
    Ribi EE; Granger DL; Milner KC; Strain SM
    J Natl Cancer Inst; 1975 Nov; 55(5):1253-7. PubMed ID: 173865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of surfactant concentration on the antitumor activity of emulsified components of mycobacteria.
    Yarkoni E; Rapp HJ
    Cancer Res; 1980 Apr; 40(4):975-8. PubMed ID: 7357563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of cancer with nonliving mycobacteria and cord factor (trehalose-6,6'-dimycolate) in aqueous medium.
    Bekierkunst A
    J Natl Cancer Inst; 1976 Oct; 57(4):963-4. PubMed ID: 187785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of cryosurgical treatment of experimental intradermal tumors to eradicate microscopic lymph node metastases in guinea pigs.
    Javadpour N; Bagley DH; Zbar B
    J Natl Cancer Inst; 1979 Jun; 62(6):1479-81. PubMed ID: 286120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report.
    Klein WR; Ruitenberg EJ; Steerenberg PA; de Jong WH; Kruizinga W; Misdorp W; Bier J; Tiesjema RH; Kreeftenberg JG; Teppema JS; Rapp HJ
    J Natl Cancer Inst; 1982 Nov; 69(5):1095-103. PubMed ID: 6957655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy with nonviable microbial components.
    Ribi E; Milner KC; Granger DL; Kelly MT; Yamamoto K; Brehmer W; Parker R; Smith RF; Strain SM
    Ann N Y Acad Sci; 1976; 277(00):228-38. PubMed ID: 187099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E; Jauhiainen K; Alfthan O
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract]   [Full Text] [Related]  

  • 33. Bacillus Calmette-Guérin cell wall immunotherapy of intramuscular and metastatic Morris rat hepatomas.
    Wepsic HT; Tracey RS; Sell S; Harris S; Ribi E; Morris H
    Cancer Res; 1978 May; 38(5):1217-22. PubMed ID: 205358
    [No Abstract]   [Full Text] [Related]  

  • 34. Ultrastructural studies of histiocyte-tumor cell interactions during tumor regression after intralesional injection of Mycobacterium bovis.
    Snodgrass MJ; Hanna MG
    Cancer Res; 1973 Apr; 33(4):701-16. PubMed ID: 4348772
    [No Abstract]   [Full Text] [Related]  

  • 35. Biologically active components from mycobacterial cell walls. III. Production of experimental allergic encephalomyelitis in guinea-pigs.
    Meyer TJ; Azuma I; Ribi EE
    Immunology; 1975 Feb; 28(2):219-29. PubMed ID: 804436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant-antigen requirements for active specific immunotherapy of microscopic metastases remaining after surgery.
    Ashley MP; Zbar B; Hunter JT; Rapp HJ; Sugimoto T
    Cancer Res; 1980 Nov; 40(11):4197-203. PubMed ID: 7471060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.
    Zbar B; Bernstein ID; Bartlett GL; Hanna MG; Rapp HJ
    J Natl Cancer Inst; 1972 Jul; 49(1):119-30. PubMed ID: 4338767
    [No Abstract]   [Full Text] [Related]  

  • 39. Eradication by immunization with mycobacterial vaccines and tumor cells of microscopic metastases remaining after surgery.
    Zbar B; Canti G; Ashley MP; Rapp HJ; Hunter JT; Ribi E
    Cancer Res; 1979 May; 39(5):1597-603. PubMed ID: 427799
    [No Abstract]   [Full Text] [Related]  

  • 40. Suppression and immunotherapy of the guinea pig line 10 hepatocarcinoma mediated by heat-killed disrupted Mycobacterium bovis strain Bacillus Calmette-Guérin.
    Minden P; Mathews HL
    Cancer Res; 1980 Sep; 40(9):3214-7. PubMed ID: 6159072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.